Optimising Hip Mobility, Hamstring Flexibility and Performance Using Lightback

Last updated: February 5, 2025
Sponsor: Universidad Católica de Ávila
Overall Status: Active - Recruiting

Phase

N/A

Condition

Athletic Injuries

Treatment

LIGHTBACK

Placebo

Clinical Study ID

NCT06811883
31/01/2025
  • Ages 18-65
  • All Genders

Study Summary

In athletics, in the sprint and hurdles disciplines, muscle injuries account for a significant proportion of injuries. The hamstrings are particularly vulnerable, accounting for between 12% and 26% of all injuries in these sports. A single-blind study was conducted on 20 hurdler patients with the intention of assessing hip mobility, hamstring flexibility and performance. To collect this data, the research team will conduct examinations and interviews with the athletes in two groups: an experimental group using LightBack and a placebo group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Sprinters and hurdlers aged 18 to 30 years.

  • No history of recent (less than 6 months) hamstring or hip injury.

  • Signed informed consent.

Exclusion

Exclusion Criteria:

  • Cruciate or hamstring tears less than 6 months old;

  • Hip and back surgery less than 3 months old;

  • Chronic or acute back problems;

  • Pregnancy;

  • Osteoporosis

  • Tumours, bone cancer of the hip and pelvis;

  • Direct trauma to the back of the thigh less than 6 months old.

  • Orthopaedic or neurological pathologies affecting mobility or muscle activation.

  • Participation in another specific training protocol

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: LIGHTBACK
Phase:
Study Start date:
January 31, 2025
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • Universidad Pontificia de Salamanca

    Salamanca, 27005
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.